ADMA Biologics (ADMA) Stock: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$9.93
-0.10 (-1.00%)
▼
5d:
+4.31%
30d:
+6.43%
90d:
+10.95%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 16, 2026 at $8.90 · last confirmed Sep 25, 2026
Strength: 5.2/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.67
Based on 11.2% avg growth
INTRINSIC VALUE TODAY
$11.59
14.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $9.93, which is considered extended relative to its 30-day fair value range of $9.14 to $9.82. The stock's valuation (Forward PE: 10.5) is in line with its historical norms (11.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.3% over the next few years. This pessimistic expectation contrasts with the company's recent 14.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ADMA is in a strong uptrend. Immediate support is located at $8.81, while resistance sits at $10.26.
Market Sentiment: ADMA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+71.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADMA is in a strong uptrend. Immediate support is located at $8.81, while resistance sits at $10.26.
Market Sentiment: ADMA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+71.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.14 -
$9.82
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 71.2% below Wall St target ($17.00)
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.14 -
$9.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.81
Resistance Level
$10.26
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.53
Wall Street Target
$17.00
(+71.2%)
Revenue Growth (YoY)
2.0%
Earnings Growth (YoY)
14.3%
Profit Margin
33.0%
Valuation Discount vs History
-3.3% cheaper
PE vs Historical
10.5 vs 11.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.3%
(market-implied from PE analysis)
1-Year Target
$9.60
(-3%)
2-Year Target
$9.29
(-7%)
3-Year Target
$8.98
(-10%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$9.98
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 18.4%)
$31.94
(+222%)
Base:
(SPY PE: 10.5, Growth: 18.4%)
$16.48
(+66%)
Bear:
(PE: 8.9, Growth: 18.4%)
$14.01
(+41%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.33 | Current EPS (TTM): $0.70
Bull Case
$14.87
(+50%)
Analyst growth 34.8%, PE expands to 15.8
Base Case
$13.52
(+36%)
Market implied 34.8%, PE stable at 14.3
Bear Case
$6.82
(-31%)
Severe decline -20.0%, PE contracts to 12.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 11.7
Stabilization Target:
$11.04
(+11.1%)
PE Expansion Potential:
+11.1%
Share & Embed Analysis
Last updated: October 01, 2026 10:22 PM ET
Data refreshes hourly during market hours. Next update: 11:22 PM
Data refreshes hourly during market hours. Next update: 11:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 68 BUY |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
